The use of monoclonal antibodies for cancer therapy has achieved considerable success in recent years.2, 3 One such antibody is cetuximab, which is a human–mouse chimeric monoclonal IgG1 antibody targeted against the epidermal growth factor receptor (EGFR).1, 4, 5 Recently, cetuximab has been used to treat patients with colorectal cancer and HNSCC. Here, EGFR is linked to colorectal cancer.